News
While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...
Sandoz is a global leader in the generics and biosimilars sector. Click here to read why I think spinning off SDZNY stock was a good move by Novartis.
We have successfully executed the spin-off of Sandoz, allowing us to fully focus on high-value innovative medicines,” Novartis CEO Vas Narasimhan, MD said in a statement. “Our growth drivers, ...
On Oct 4, 2023, Novartis announced it has completed its plan to spin-off Sandoz, its generics and biosimilars business, into an independent company. The spin-off took place through a dividend-in-kind ...
Summary Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off.
Sandoz has completed its separation from Novartis, with the business now continuing as an independent spin-off company. The separation allows Novartis to fully focus its attention on innovative ...
Sandoz starts share trading on SIX Swiss Exchange as independent company after 100 percent spin-off from Novartis ...
The debut made Sandoz the largest new entrant to the Swiss stock exchange since 2019, when another Novartis spin-off, eyecare company Alcon, was valued at about 28 billion francs.
The Spin-off of Sandoz enables Novartis to complete its transformation to become a leading, focused medicines company. With capital allocation and management attention fully focused on innovative ...
Novartis expects the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs, will commence on Oct. 4.
Novartis has officially confirmed it’s spin-off, Sandoz, with trading of new Sandoz Group AG shares and American Depositary Receipts (ADRs) to commence on Oct. 4. Expected to be listed and traded on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results